Arrowhead Pharmaceuticals and Horizon Therapeutics announced a research and development collaboration to advance an RNA interference (RNAi) therapeutic for uncontrolled gout.
RNAi-focused Atalanta Therapeutics launched with $110 million in combined Series A funding and collaboration deals with Genentech and Biogen to address diseases related to the central nervous system, including Huntington’s, Alzheimer’s and Parkinson’s diseases.
Alnylam Pharmaceuticals presented complete results from the company’s ILLUMINATE-B Phase III study in children under 6 years with primary hyperoxaluria type 1 (PH1), a rare disorder affecting the kidneys.
Alnylam Pharmaceuticals reported positive results for the ILLUMINATE-B Phase III clinical trial evaluating the RNAi therapeutic lumasiran in young children with primary hyperoxaluria type 1 (PH1).
Investment firm Blackstone Life Sciences and Alnylam Pharmaceuticals announced a broad strategic collaboration worth up to $2 billion.
Stuart Hughes was named CEO of Pathios Therapeutics Ltd.
Dicerna Pharmaceuticals Inc. and Novo Nordisk A/S announced an agreement to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases using Dicerna’s proprietary GalXC RNAi platform technology.
Cambridge, Mass.-based Dicerna Pharmaceuticals signed a research collaboration and licensing deal with Switzerland’s Roche for chronic hepatitis B virus therapies that could hit $1.67 billion.
Mallinckrodt plc and Silence Therapeutics plc announced a collaboration that will allow the companies to develop and commercialize RNAi drug targets designed to inhibit or ‘silence’ the complement cascade, a group of proteins that are involved in the immune system and that play a role in the development of inflammation.
Dicerna Pharmaceuticals and Eli Lilly struck a deal to use an RNAi technology platform for up to 10 cardio-metabolic, neurodegeneration and pain targets.